Characterization of breast cancers and therapy response by MRS and quantitative gene expression profiling in the choline pathway.
Tumor choline metabolites have potential for use as diagnostic indicators of breast cancer phenotype and can be non-invasively monitored in vivo by MRS. Extract studies have determined that the principle diagnostic component of these peaks is phosphocholine (PCho), the biosynthetic precursor to the membrane phospholipid, phosphatidylcholine (PtdCho). The ability to resolve and quantify PCho in vivo would improve the accuracy of this putative diagnostic tool. In addition, determining the biochemical mechanisms underlying these metabolic perturbations will improve the understanding of breast cancer and may suggest potential molecular targets for drug development. Reported herein is the in vivo resolution and quantification of PCho and glycerophosphocholine (GPC) in breast cancer xenografts in SCID mice via image-guided 31P MRS, localized to a single voxel. Tumor metabolites are also detected using ex vivo extracts and high-resolution NMR spectroscopy and are quantified in the metastatic tumor line, MDA-mb-231. Also reported is the quantification of cytosolic and lipid metabolites in breast cells of differing cancer phenotype, and the identification of metabolites that differ among these cell lines. In cell extracts, PCho and the PtdCho breakdown products, lysophosphatidylcholine, GPC and glycerol 3-phosphate, are all raised in breast cancer lines relative to an immortalized non-malignant line. These metabolic differences are in direct agreement with differences in expression of genes encoding enzymes in the choline metabolic pathway. Results of this study are consistent with previous studies, which have concluded that increased choline uptake, increased choline kinase activity, and increased phosholipase-mediated turnover of PtdCho contribute to the observed increase in PCho in breast cancer. In addition, this study presents evidence suggesting a specific role for phospholipase A2-mediated PtdCho catabolism. Gene expression changes following taxane therapy are also reported and are consistent with previously reported changes in choline metabolites after the same therapy in the same tumor model.
Morse
David L
DL
BIO5 Institute, University of Arizona, Tucson, AZ 85724, USA.
Carroll
Danielle
D
Day
Sam
S
Gray
Heather
H
Sadarangani
Pooja
P
Murthi
Shiva
S
Job
Constantin
C
Baggett
Brenda
B
Raghunand
Natarajan
N
Gillies
Robert J
RJ
D000818:Animals; D002457:Cell Extracts; D045744:Cell Line, Tumor; D002794:Choline / Q000378:metabolism*; D000077143:Docetaxel; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D052138:Genes, Neoplasm; D006801:Humans; D009682:Magnetic Resonance Spectroscopy; D015674:Mammary Neoplasms, Animal / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D053858:Metabolic Networks and Pathways / Q000187:drug effects / Q000235:genetics*; D051379:Mice; D016513:Mice, SCID; D010641:Phenotype; D010713:Phosphatidylcholines / Q000378:metabolism; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D043823:Taxoids / Q000494:pharmacology / Q000627:therapeutic use; D023041:Xenograft Model Antitumor Assays
D002457:Cell Extracts; D010713:Phosphatidylcholines; D012333:RNA, Messenger; D043823:Taxoids; D000077143:Docetaxel; D002794:Choline